A Phase I Study in Resminostat monotherapy and S-1/Resminostat therapy in Patients with biliary tract or pancreatic cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 13 Sep 2017
At a glance
- Drugs Resminostat (Primary) ; Gimeracil/oteracil/tegafur
- Indications Biliary cancer; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Yakult Honsha
- 13 Sep 2017 Results presented in a 4SC media release.
- 13 Sep 2017 Results published in the Media Release
- 13 Sep 2017 According to a 4SC media release, results of this trial (n=27) were presented at the ESMO 2017 Congress by Yakult Honsha.